Domo signs strategic collaboration agreement with AWS for AI solutions
Investing.com - H.C. Wainwright has reiterated a Buy rating and $80.00 price target on Protagonist Therapeutics (NASDAQ:PTGX), a $3.4 billion market cap biotech company, highlighting its strategic approach to targeting major indications. According to InvestingPro data, analysts maintain a Strong Buy consensus with price targets ranging from $41 to $82.
The research firm noted that Protagonist has built credibility through successful development of rusfertide and icotrokinra, which created significant shareholder value through partnerships with Takeda and Janssen. This success is reflected in the company’s impressive 57% return over the past year, with InvestingPro analysis showing strong financial health metrics and a solid balance sheet with more cash than debt.
H.C. Wainwright pointed to PN-881, an oral IL-17 antagonist, as demonstrating the company’s ability to develop highly potent oral peptides that appear to rival injectable monoclonal antibodies like Bimzelx in potency.
The firm expressed particular interest in PN-477, Protagonist’s peptide GLP-1/GIPR/GCGR tri-agonist for obesity treatment, which reportedly outperformed Eli Lilly (NYSE:LLY)’s retatrutide in weight loss studies with Cynomoglus monkeys and dogs.
H.C. Wainwright views Protagonist’s development of both oral and subcutaneous formulations of PN-477 as a strategic advantage, offering flexibility to tailor treatment beyond simply the route of administration.
In other recent news, Protagonist Therapeutics has been the focus of multiple analyst reports highlighting significant developments around its drug candidate, rusfertide, for polycythemia vera (PV). The company presented comprehensive data at the ASCO conference, showcasing rusfertide’s ability to improve symptoms and manage hematocrit levels in PV patients. Citi initiated coverage with a Buy rating and a $72 price target, citing strong potential for rusfertide and projecting 2032 combined worldwide revenues of $700 million, slightly above consensus estimates. H.C. Wainwright reaffirmed its Buy rating with an $80 price target, emphasizing rusfertide’s potential to become a standard of care in PV treatment. Clear Street, while maintaining a Buy rating, lowered its price target to $62, reflecting a reassessment of the company’s strategy and concerns about introducing another costly therapy. BTIG also reiterated a Buy rating with an $82 price target, underscoring rusfertide’s efficacy in reducing phlebotomies and improving patient quality of life. JPMorgan maintained an Overweight rating with a $66 price target, noting that recent data could alter the current treatment paradigm for PV. These developments highlight the growing confidence in rusfertide’s potential impact on PV treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.